About China Biologic Products (NASDAQ:CBPO)
China Biologic Products Holdings, Inc. is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates through the manufacture and sales of human plasma products segment. China Biologic has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across nine categories.The Company's products include human albumin, human immunoglobulin, immunoglobulin for intravenous injection (IVIG), human hepatitis B immunoglobulin, human rabies immunoglobulin, human tetanus immunoglobulin, placenta polypeptide, Factor VIII and human prothrombin complex concentrate (PCC).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:CBPO
- CUSIP: N/A
- Web: www.chinabiologic.com
- Market Cap: $2.21 billion
- Outstanding Shares: 27,238,000
- 50 Day Moving Avg: $90.93
- 200 Day Moving Avg: $102.24
- 52 Week Range: $76.26 - $125.99
Sales & Book Value:
- Trailing P/E Ratio: 21.14
- Foreward P/E Ratio: 14.53
- P/E Growth: 1.45
- Annual Revenue: $344.89 million
- Price / Sales: 6.41
- Book Value: $20.26 per share
- Price / Book: 4.01
- EBITDA: $155.64 million
- Net Margins: 31.55%
- Return on Equity: 21.86%
- Return on Assets: 18.83%
- Current Ratio: 5.21%
- Quick Ratio: 3.24%
- Average Volume: 324,763 shs.
- Beta: 1.75
- Short Ratio: 6.28
Frequently Asked Questions for China Biologic Products (NASDAQ:CBPO)
What is China Biologic Products' stock symbol?
China Biologic Products trades on the NASDAQ under the ticker symbol "CBPO."
How were China Biologic Products' earnings last quarter?
China Biologic Products, Inc. (NASDAQ:CBPO) posted its quarterly earnings results on Wednesday, August, 2nd. The company reported $1.35 EPS for the quarter, beating the Zacks' consensus estimate of $1.30 by $0.05. The business had revenue of $89.28 million for the quarter, compared to analysts' expectations of $97.33 million. China Biologic Products had a return on equity of 21.86% and a net margin of 31.55%. The business's quarterly revenue was down 2.3% on a year-over-year basis. During the same period last year, the firm earned $1.26 earnings per share. View China Biologic Products' Earnings History.
Where is China Biologic Products' stock going? Where will China Biologic Products' stock price be in 2017?
3 equities research analysts have issued 12-month target prices for China Biologic Products' stock. Their forecasts range from $135.00 to $140.00. On average, they expect China Biologic Products' stock price to reach $137.50 in the next year. View Analyst Ratings for China Biologic Products.
Who are some of China Biologic Products' key competitors?
Some companies that are related to China Biologic Products include Clovis Oncology (CLVS), Sarepta Therapeutics (SRPT), BeiGene (BGNE), Agios Pharmaceuticals (AGIO), AveXis (AVXS), GW Pharmaceuticals PLC (GWPH), Spark Therapeutics (ONCE), Loxo Oncology (LOXO), Halozyme Therapeutics (HALO), Aerie Pharmaceuticals (AERI), Prothena Corporation PLC (PRTA), Ultragenyx Pharmaceutical (RARE), Array BioPharma (ARRY), Insmed (INSM), Intercept Pharmaceuticals (ICPT), NovoCure Limited (NVCR), Radius Health (RDUS) and Acceleron Pharma (XLRN).
Who are China Biologic Products' key executives?
China Biologic Products' management team includes the folowing people:
- David Gao, Chairman of the Board, President, Chief Executive Officer
- Ming Yang CPA, Chief Financial Officer
- Zhijing Liu, Corporate Vice President
- Ming Yin, Senior Corporate Vice President
- Gang Yang, Corporate Vice President, General Manager of Guizhou Taibang
- David Hui Li, Director
- Joseph J. Chow, Independent Director
- Wenfang Liu, Independent Director
- Yungang Lu, Independent Director
- Xiaosheng Shao, Independent Director
Who owns China Biologic Products stock?
China Biologic Products' stock is owned by many different of retail and institutional investors. Top institutional investors include Hermes Investment Management Ltd. (2.62%), New Silk Road Investment PTE Ltd. (0.70%) and Strs Ohio (0.03%). Company insiders that own China Biologic Products stock include David Gao, Ming Yang, Ming Yin, Sean Shao, Wenfang Liu, Wp X Biologics Llc, Zhijing Cbpo Liu and Zhijun Tong. View Institutional Ownership Trends for China Biologic Products.
Who bought China Biologic Products stock? Who is buying China Biologic Products stock?
How do I buy China Biologic Products stock?
Shares of China Biologic Products can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is China Biologic Products' stock price today?
MarketBeat Community Rating for China Biologic Products (NASDAQ CBPO)MarketBeat's community ratings are surveys of what our community members think about China Biologic Products and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of China Biologic Products stock can currently be purchased for approximately $81.22.
Consensus Ratings for China Biologic Products (NASDAQ:CBPO) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Hold Rating, 2 Buy Ratings|
|Consensus Rating:||Buy (Score: 2.67)|
|Consensus Price Target: ||$137.50 (69.29% upside)|Consensus Price Target History for China Biologic Products (NASDAQ:CBPO)
Analysts' Ratings History for China Biologic Products (NASDAQ:CBPO)
(Data available from 10/24/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|8/4/2017||Jefferies Group LLC||Reiterated Rating||Buy||Low|
|5/30/2017||Goldman Sachs Group, Inc. (The)||Initiated Coverage||Neutral -> Neutral||Medium|
|3/3/2017||Morgan Stanley||Reiterated Rating||Overweight||$135.00||N/A|
|7/5/2016||Credit Suisse Group||Upgrade||Neutral -> Outperform||N/A|
|1/7/2016||Deutsche Bank AG||Boost Price Target||Buy||$149.00 -> $162.00||N/A|
Earnings History for China Biologic Products (NASDAQ:CBPO)Earnings History by Quarter for China Biologic Products (NASDAQ CBPO)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/2/2017||6/30/2017||$1.30||$1.35||$97.33 million||$89.28 million||View||Listen|
|2/23/2017||Q416||$0.84||$0.95||$76.61 million||$77.60 million||View||N/A|
|11/2/2016||Q316||$1.05||$1.22||$88.46 million||$86.50 million||View||N/A|
|8/4/2016||Q216||$1.16||$1.10||$87.60 million||$91.40 million||View||N/A|
|5/4/2016||Q116||$0.88||$0.94||$74.00 million||$85.60 million||View||N/A|
|2/25/2016||Q415||$0.55||$0.74||$66.77 million||$68.30 million||View||Listen|
|11/3/2015||Q315||$0.81||$0.82||$75.30 million||$78.80 million||View||N/A|
|8/5/2015||Q215||$0.87||$0.99||$71.75 million||$79.10 million||View||N/A|
|5/6/2015||Q1 15||$0.84||$0.87||$70.35 million||View||N/A|
|11/5/2014||Q4 14||$0.43||$0.48||$63.00 million||$68.92 million||View||N/A|
|3/12/2014||Q413||$0.38||$0.35||$41.50 million||$42.60 million||View||N/A|
|11/5/2013||Q313||$0.42||$0.56||$47.20 million||$53.20 million||View||N/A|
|11/8/2012||Q312||$0.54||$41.30 million||$53.10 million||View||N/A|
Earnings Estimates for China Biologic Products (NASDAQ:CBPO)
Current Year EPS Consensus Estimate: $4.93 EPS
Next Year EPS Consensus Estimate: $5.59 EPS
Dividend History for China Biologic Products (NASDAQ:CBPO)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for China Biologic Products (NASDAQ:CBPO)
Insider Ownership Percentage: 2.73%Insider Trades by Quarter for China Biologic Products (NASDAQ:CBPO)
Institutional Ownership Percentage: 72.82%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|5/9/2017||Zhijing Cbpo Liu||Insider||Sell||7,500||$116.49||$873,675.00|| |
|3/2/2017||Sean Shao||Director||Sell||20,000||$100.78||$2,015,600.00|| |
|3/1/2017||David Gao||CEO||Sell||116,653||$100.63||$11,738,791.39|| |
|8/15/2016||Ming Yang||CFO||Sell||21,092||$124.32||$2,622,157.44|| |
|8/15/2016||Wenfang Liu||Director||Sell||2,900||$124.32||$360,528.00|| |
|8/15/2016||Zhijing Cbpo Liu||Insider||Sell||1,968||$124.32||$244,661.76|| |
|6/8/2016||Wp X Biologics Llc||Director||Sell||2,775,000||$111.00||$308,025,000.00|| |
|5/20/2016||Ming Yang||CFO||Sell||13,908||$113.64||$1,580,505.12|| |
|5/20/2016||Ming Yin||VP||Sell||19,618||$113.64||$2,229,389.52|| |
|3/11/2016||Zhijing Cbpo Liu||VP||Sell||282||$108.00||$30,456.00|| |
|3/7/2016||Wp X Biologics Llc||Director||Sell||4,257,000||$107.00||$455,499,000.00|| |
|12/7/2015||Zhijun Tong||Director||Sell||15,000||$118.33||$1,774,950.00|| |
|11/4/2015||David Gao||CEO||Sell||95,991||$115.60||$11,096,559.60|| |
|11/2/2015||David Gao||CEO||Sell||12,891||$112.26||$1,447,143.66|| |
|10/29/2015||David Gao||CEO||Sell||71,118||$110.21||$7,837,914.78|| |
|10/26/2015||David Gao||CEO||Sell||59,542||$105.22||$6,265,009.24|| |
|10/20/2015||David Gao||CEO||Sell||258||$105.00||$27,090.00|| |
|10/19/2015||David Gao||CEO||Sell||200||$105.03||$21,006.00|| |
|9/15/2015||Ming Yang||CFO||Sell||9,000||$94.56||$851,040.00|| |
|9/15/2015||Ming Yin||VP||Sell||20,508||$95.55||$1,959,539.40|| |
|9/14/2015||Ming Yang||CFO||Sell||11,304||$97.08||$1,097,392.32|| |
|9/14/2015||Wenfang Liu||Director||Sell||2,717||$97.02||$263,603.34|| |
|9/14/2015||Zhijing Cbpo Liu||VP||Sell||6,786||$99.29||$673,781.94|| |
|6/15/2015||Wp X Biologics Llc||Director||Sell||2,645,000||$100.28||$265,240,600.00|| |
|11/21/2014||Zhijing Cbpo Liu||VP||Sell||8,000||$68.95||$551,600.00|| |
|11/10/2014||Sean Shao||Director||Sell||72,500||$62.75||$4,549,375.00|| |
|11/10/2014||Zhijing Cbpo Liu||VP||Sell||7,500||$62.75||$470,625.00|| |
|9/15/2014||Gang Cbpo Yang||VP||Sell||2,454||$54.00||$132,516.00|| |
|9/15/2014||Ming Yang||CFO||Sell||6,164||$54.00||$332,856.00|| |
|9/12/2014||Ming Yin||VP||Sell||3,073||$54.00||$165,942.00|| |
|9/12/2013||Wenfang Liu||Director||Sell||2,524||$25.00||$63,100.00|| |
|5/14/2013||Wp X Biologics Llc||Director||Buy||3,112,920||$20.00||$62,258,400.00|| |
Headline Trends for China Biologic Products (NASDAQ:CBPO)
Latest Headlines for China Biologic Products (NASDAQ:CBPO)
Loading headlines, please wait.
China Biologic Products (CBPO) Chart for Tuesday, October, 24, 2017